Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences, Inc. (XBIO)
:XBIO
Total Valuation
Xenetic Biosciences has a market cap or net worth of $6.14M. The enterprise value is -$6.24M.
Market Cap$6.14M
Enterprise Value-$6.24M
Share Statistics
Xenetic Biosciences has 1,542,139 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,542,139
Owned by Insiders―
Owned by Institutions1.58%
Financial Efficiency
Xenetic Biosciences’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -69.99%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-69.99%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee1.25M
Profits Per Employee-1.98M
Employee Count2
Asset Turnover0.36
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Xenetic Biosciences is -1.55. Xenetic Biosciences’s PEG ratio is 0.04.
PE Ratio-1.55
PS Ratio0.00
PB Ratio0.30
Price to Fair Value1.02
Price to FCF-0.79
Price to Operating Cash Flow-0.87
PEG Ratio0.04
Income Statement
In the last 12 months, Xenetic Biosciences had revenue of 2.50M and earned -3.96M in profits. Earnings per share was -2.57.
Revenue2.50M
Gross Profit2.50M
Operating Income-4.20M
Pretax Income-3.96M
Net Income-3.96M
EBITDA-4.20M
Earnings Per Share (EPS)-2.57
Cash Flow
In the last 12 months, operating cash flow was -2.66M and capital expenditures 0.00, giving a free cash flow of -2.66M billion.
Operating Cash Flow-2.66M
Free Cash Flow-2.66M
Free Cash Flow per Share-1.72
Dividends & Yields
Xenetic Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-5.01%
50-Day Moving Average3.20
200-Day Moving Average3.63
Relative Strength Index (RSI)59.67
Average Volume (3m)125.12K
Important Dates
Xenetic Biosciences upcoming earnings date is Aug 8, 2025, TBA (Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Xenetic Biosciences as a current ratio of 7.37, with Debt / Equity ratio of 0.00%
Current Ratio7.37
Quick Ratio7.37
Debt to Market Cap0.00
Net Debt to EBITDA1.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Xenetic Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Xenetic Biosciences EV to EBITDA ratio is <0.01, with an EV/FCF ratio of <0.01.
EV to Sales>-0.01
EV to EBITDA<0.01
EV to Free Cash Flow<0.01
EV to Operating Cash Flow<0.01
Balance Sheet
Xenetic Biosciences has $5.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$5.16M billion.
Cash & Marketable Securities$5.16M
Total Debt$0.00
Net Cash-$5.16M
Net Cash Per Share-$3.35
Tangible Book Value Per Share$3.90
Margins
Gross margin is 98.42%, with operating margin of -168.16%, and net profit margin of -158.39%.
Gross Margin98.42%
Operating Margin-168.16%
Pretax Margin-158.39%
Net Profit Margin-158.39%
EBITDA Margin-168.16%
EBIT Margin-168.16%
Analyst Forecast
The average price target for Xenetic Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-1.56%
EPS Growth Forecast5.01%